LOGIN  |  REGISTER
C4 Therapeutics

Community Health Systems to Participate in the 2023 BofA Securities Leveraged Finance Conference

November 21, 2023 | Last Trade: US$4.05 0.27 -6.25

FRANKLIN, Tenn. / Nov 21, 2023 / Business Wire / Community Health Systems, Inc. (NYSE:CYH) today announced that management will participate in the 2023 BofA Securities Leveraged Finance Conference to be held November 27 – 29, 2023.

The investor presentation will begin at 8:50 a.m. Eastern time, 7:50 a.m. Central time, on Tuesday, November 28, 2023, and will be available to investors via a live audio webcast. A link to the broadcast can be found at the investor relations section of the Company’s website, www.chs.net, and a replay will be available using that same link.

About Community Health Systems, Inc.

Community Health Systems, Inc. is one of the nation’s largest healthcare companies. The Company's affiliates are leading providers of healthcare services, developing and operating healthcare delivery systems in 41 distinct markets across 15 states. CHS subsidiaries own or lease 74 affiliated hospitals with 12,000 beds and operate more than 1,000 sites of care, including physician practices, urgent care centers, freestanding emergency departments, occupational medicine clinics, imaging centers, cancer centers and ambulatory surgery centers. Shares in Community Health Systems, Inc. are traded on the New York Stock Exchange under the symbol “CYH.” The Company’s headquarters are located in Franklin, Tennessee, a suburb south of Nashville. More information about the Company can be found on its website at www.chs.net.

Viking Therapeutics

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB